Eric Dusseux, MD, MSc, MBA
Chief Executive Officer
Prior to joining Bionik, Dr. Dusseux was President of Europe and a director for Auregen BioTherapeutics SA, a 3D bioprinting tissue engineering biotechnology company headquartered in Switzerland, that he formed while at Bemido SA, a family office, with the support of Gurnet Point Capital and Waypoint.
From 2012 through 2016, Dr. Dusseux served as an Executive Committee Member in the Corporate Strategy Department of Sanofi Pasteur, the vaccine division of Sanofi. Among other responsibilities, Dr. Dusseux, Vice-President Corporate Strategy, was responsible for business intelligence, strategic and business planning, and corporate development.
Before joining Sanofi Pasteur, Dr. Dusseux served as Vice-President, MAGE-A3 Medicines Development Leader, within the Immunotherapeutics Business Unit at GSK Biologicals, a division of GlaxoSmithKline, in charge of therapeutic vaccines against cancer.
Dr. Dusseux also gained significant experience providing strategic advice for numerous pharmaceutical, medical device, payer and biotechnology clients, while working for the Boston Consulting Group from 2002 to 2007.
Dr. Dusseux is a Medical Doctor, specializing in Public Health. Dr. Dusseux also holds a Master of Science in Physical Chemistry and is a graduate of the French Business School H.E.C. in Paris (MBA, Isa).
Co-Founder and Chief Technology Officer
Mr. Prywata is the co-founder and Chief Technology Officer of Bionik Laboratories. He studied biomedical engineering at Ryerson University and has a proven track record of inventing and winning technology showcases. While attending Ryerson, Mr. Prywata co-invented the world’s first robotic, prosthetic arm that is controlled by brain signals. Equally impressive is his strong understanding of developing technologies that address significant and untapped markets. He is responsible for raising the initial capital to found Bionik and turn numerous concepts into products.
Leslie N. Markow, CPA, CA, CPA (Illinois), C.Dir.
Chief Financial Officer
Ms. Markow has served as the Company’s Chief Financial Officer since September 2014. She has over 25 years of finance and accounting leadership experience and holds a CPA and CA in Canada, US CPA (Illinois) and Chartered Director designations. Ms. Markow is the former Chief Financial Officer of Stewardship Ontario and Blue Ocean NutraSciences Inc., and Director of Client Service for Resources Global Professionals, a Nasdaq-listed global consulting firm. For 11 years she held various positions, including Chief Administrative Officer at SunOpta Inc. a Nasdaq/TSX listed public company. Ms. Markow started her career in 1983 with PricewaterhouseCoopers, ultimately holding a position as Senior Audit Manager. She is a member of the Board of Directors and Chairperson of the Audit Committee of Jemtec Inc. Ms. Markow also is a member of Financial Executives Canada, where she is a past National Board Director, Toronto Board Director, Toronto Chapter President and the winner of the Toronto Leadership Award. She is a faculty member of The Directors College, which is a joint venture of McMaster University and The Conference Board of Canada.
Malcolm G. Bock
Vice President of Engineering
Mr. Bock previously served as the Vice President of Engineering at Respiratory Motion, where he was responsible for creating a product pipeline and technology roadmap, and bringing the company's first product from concept to launch in 10-months' time. Prior to that, Mr. Bock served as the Senior Director of Global R&D for Covidien Ltd., a spin-off of Tyco International, where he was responsible for R&D and launching 15 new products, including both durable electro-mechanical systems and single-use devices, over a 10-year period. In 2011, he was awarded Covidien Inventor of the Year. Over the course of his career, Mr. Bock has launched over 38 new products and was awarded Best Divisional Vitality Index, and Best New Product for his work at Covidien. He has also been awarded 30 patents, with an additional 28 patents pending.